Nuvectis Pharma, Inc.
NVCT
$9.07
-$0.42-4.43%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.82% | 3.84% | 9.46% | 13.91% | 25.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.36% | -10.85% | -1.52% | 15.64% | 21.42% |
| Operating Income | 9.36% | 10.85% | 1.52% | -15.64% | -21.42% |
| Income Before Tax | 14.65% | 13.25% | 5.50% | -10.85% | -16.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.65% | 13.25% | 5.50% | -10.85% | -16.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.65% | 13.25% | 5.50% | -10.85% | -16.64% |
| EBIT | 9.36% | 10.85% | 1.52% | -15.64% | -21.42% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 22.34% | 21.00% | 15.61% | 2.00% | 3.51% |
| Normalized Basic EPS | 18.81% | 20.78% | 15.09% | 0.64% | 2.27% |
| EPS Diluted | 22.34% | 21.00% | 15.61% | 2.00% | 3.51% |
| Normalized Diluted EPS | 18.81% | 20.78% | 15.09% | 0.64% | 2.27% |
| Average Basic Shares Outstanding | 10.03% | 10.25% | 12.20% | 14.04% | 22.96% |
| Average Diluted Shares Outstanding | 10.03% | 10.25% | 12.20% | 14.04% | 22.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
